Alamar Biosciences to Report Second Quarter 2026 Financial Results on August 10, 2026
Rhea-AI Summary
Alamar Biosciences (Nasdaq: ALMR) announced it will report its second quarter 2026 financial results after market close on Monday, August 10, 2026. Management will host a webcast conference call at 1:30 p.m. PT / 4:30 p.m. ET, accessible via the Investors section of the company website, with an archived replay available.
Positive
- None.
Negative
- None.
Market reaction after 2Q26 earnings report date: ALMR -3.40% in the Jul 15 session
In the Jul 15 session, ALMR declined 3.40%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jul 13 | Partnership announcement | Positive | -3.6% | National proteomics initiative profiling 21,000 plasma samples from 10,000 participants. |
| Jul 10 | Conference data highlight | Positive | +7.3% | NULISA platform featured in over 140 AAIC 2026 presentations. |
| Jul 07 | Product launch | Positive | -1.7% | Launch of first multiplexed blood-based immunoassay for eMTBR-Tau. |
| May 08 | Earnings report | Neutral | +1.3% | Q1 2026 revenue rose to $26.0M with 99% year-over-year growth. |
| May 05 | Conference participation | Neutral | -0.3% | Planned presentation at BofA Securities 2026 Healthcare Conference. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news has more often seen ALMR trade in line with generally positive catalysts, though some favorable partnership and product announcements were followed by next-day declines.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FREMONT, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in Precision Proteomics dedicated to enabling the earliest detection of disease, today announced it will report financial results for the second quarter 2026 after market close on Monday, August 10, 2026. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Live audio of the webcast will be available on the “Investors” section of the company website at: www.alamarbio.com. The webcast will be archived and available for replay after the event.
About Alamar Biosciences
Alamar is a commercial-stage proteomics company establishing a gold standard in protein detection and analysis. Leveraging our proprietary NULISA™ technology and the ARGO™ HT System, our platform is designed to detect protein biomarkers at extremely low concentrations in blood with ultra-high sensitivity, high specificity, flexible multiplexing, broad dynamic range and seamless automation. We refer to this combination of features as “Precision Proteomics,” and believe it fills a critical gap in the field of advanced proteomics, helping researchers unlock the full spectrum of protein biomarkers across disease states. Learn more at alamarbio.com.
Investor contact:
Media contact:
